GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase III Data

GSK on Saturday unveiled new data from its Phase III RUBY program demonstrating better survival outcomes in a wide range of endometrial cancer patients treated with Jemperli (dostarlimab), potentially setting the PD-1 blocker up for a label expansion